AU 18069
Alternative Names: AU-18069Latest Information Update: 15 Jan 2024
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacokinetics and pharmacodynamics data from a preclinical study in Solid tumours and Haematological malignancies presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 01 Apr 2022 Preclinical trials in Haematological malignancies in India (unspecified route)
- 01 Apr 2022 Preclinical trials in Solid tumours in India (unspecified route)